Companies / AVE

AVECHO BIOTECHNOLOGY LIMITED

ASX:AVEPharmaceuticals, Biotechnology & Life Sciences
3.86B shares on issueASX (delayed) · snapshot 11 Sept 20263.99B fully diluted+3.3% if every option and right converts$0.021price · delayed$81.1Mmarket cap · indicative

Today’s holders own 96.8% of what they think they own, once every option and right converts.

Low
Dilution risk

Share count grew 22% in 24 months; runway 4–8 quarters; 2 cash raises in 24 months

MinimalVery high
Absolute levels — not a ranking against other companies.
Cash runway5.0 quarters of funding
Share-count growth (24m)21.8%
Raise cadence (24m)2 cash raises
Options & rights overhang3.3% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

AVECHO BIOTECHNOLOGY LIMITED's ordinary share count grew 21.8% between April 2025 and June 2026, to 3.86B shares. The company raised capital twice in the past 24 months for total disclosed proceeds of A$5.0M, most recently a A$2.5M placement in October 2025. Options and rights on issue could convert into 128M new shares, equal to 3.3% of the current share count, with the nearest expiry in August 2030; none are currently in the money. At the June 2026 quarter, the company reported A$5.7M in available cash, sufficient for 5.0 quarters of funding at its recent spending rate. No proposed securities issues are pending.

AI-generated summary of this page's cited filings · updated 7 Sept 2026
Get told when this changes
Set up alerts
Daily email alerts cover risk-level moves, new raises, pending proposed issues and option expiries for the companies you follow.
3.3%
Options & rights overhang
0.0%
In-the-money supply
2
Raises · last 12 months
5.0 qtrs
Cash cover · over 4 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 3.86B per ASX (delayed) (snapshot 11 Sept 2026).
3.25B3.50B3.75BDec 24Oct 25Sept 26Cash raise · 23 Oct 2025Cash raise · 22 Oct 20253.86B

Cash runway

5.0 qtrs
More than four quarters of funding at the recent spend rate.
Funds operations to about Sept 2027 at the reported spend rate.
$5.7M cash after burn from the quarter ended 30 June 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds. Filed with the quarterly report: $6.6M cash at quarter end (item 4.6). Our figure above carries the filed quarter-end balance forward at the reported spend rate and adds announced raise proceeds.
Free account
13 quarters on record — Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 30 June 2026.
Free account: 2 full company unlocks every month, no card.
Create free accountSee plans

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityOn issue, per this filingSource
27 Aug 20263G · unquotedORDINARY FULLY PAID3.86BAppendix 3G
30 June 20262A · quoted issueAVE : ORDINARY FULLY PAID3.86BAppendix 2A
2 June 20263G · unquotedORDINARY FULLY PAID3.83BAppendix 3G
31 May 20263H · cancellationORDINARY FULLY PAID3.83BAppendix 3H
13 May 20262A · quoted issueAVE : ORDINARY FULLY PAID3.83BAppendix 2A
Free account
14 filings on record — Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Free account: 2 full company unlocks every month, no card.
Create free accountSee plans

Capital raises

2 cash raises in the last 24 months · 2 in the last 12 months

every 0 monthsaverage gap between raises
10.6 monthssince the most recent
22 Oct 2025 – 23 Oct 2025first to most recent in this window
$2.5M
Placement
23 Oct 2025 COMPLETE
Free account
4 raises on record — Full raise history
Issue price, shares issued, brokers and stated purpose for every raise on record.
Free account: 2 full company unlocks every month, no card.
Create free accountSee plans

Forward supply

Every dated event on record that could add securities to the register — option expiries to their stated dates and proposed issues over the next 18 months, on one timeline.

Free account
1 dated event on record — Forward supply calendar
Option expiries and proposed issues on one forward timeline, with the securities each could add.
Free account: 2 full company unlocks every month, no card.
Create free accountSee plans

Placement capacity

How much stock a company can place without asking holders. Listing Rule 7.1 allows 15% of ordinary securities in any 12 months, and every Appendix 3B states how much of it an issue uses.

About 58% of the 15% placement capacity left — about 42% used by Appendix 3B filings in the last 12 months (estimate, as at 2026-09-12). The company has also placed under the additional 10% (Listing Rule 7.1A), which is not counted in this figure. Holder-approved issues and any later ratification are not deducted, so the true headroom can be higher.
Free account
Placement capacity — LR 7.1 / 7.1A
The filings behind the figure: every Appendix 3B in the window with what it says was issued under 7.1 and 7.1A, each row linked to its filing, and how many shares are left.
Free account: 2 full company unlocks every month, no card.
Create free accountSee plans

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

3.3%
Options & rights overhang · of current shares
0.0%
In-the-money supply · at current price
127.6M
Potential new shares
Aug 2030
Nearest expiry
What a price move would switch on
63.8M127.6M$0.021 now0.25× today ($0.005) — 0 of the priced supply in the money, 0.0% of shares on issue0.5× today ($0.011) — 0 of the priced supply in the money, 0.0% of shares on issue0.75× today ($0.016) — 0 of the priced supply in the money, 0.0% of shares on issue1× today ($0.021) — 0 of the priced supply in the money, 0.0% of shares on issue1.25× today ($0.026) — 0 of the priced supply in the money, 0.0% of shares on issue1.5× today ($0.032) — 127.6M of the priced supply in the money, 3.3% of shares on issue2× today ($0.042) — 127.6M of the priced supply in the money, 3.3% of shares on issue3× today ($0.063) — 127.6M of the priced supply in the money, 3.3% of shares on issue5× today ($0.105) — 127.6M of the priced supply in the money, 3.3% of shares on issue10× today ($0.210) — 127.6M of the priced supply in the money, 3.3% of shares on issue0.25×0.5×0.75×now1.25×1.5×2×3×5×10×

At $0.021 today, 0 securities are in the money (0.0% of shares on issue). No more priced supply until 1.5× today’s price, which takes it to 127.6M (3.3% of shares).

  • Priced supply in the money at the price on the axis — the curve, and the only thing on it. Ten prices, sampled: between two of them the true figure lies between the two.
CodeSecurityTypeExercise priceExpiryOn issueSource
AVEASOptionsPrice-triggered$0.0301 Aug 2030127.6MFiling

“Nil” is a stated nil exercise price: nothing is paid to convert. An em dash means the filing names no exercise price at all. Security is read from the filing’s own class description; an em dash there means the description is not one this table labels. One row is one security class, at the number stated in the most recent quotation application that restated it — linked, and dated, in the last column.

Free account
1 option line on record — In-the-money value & price ladder
What each line is worth in the money today, the price ladder to the next tranche that converts, and the filing description behind every code.
Free account: 2 full company unlocks every month, no card.
Create free accountSee plans

Director dealings

DateDirectorTypeSharesOptionsOtherValueSource
10 May 2026Matthew Patrick McNamaraSell—2.5M——3Y notice
10 May 2026Ross MurdochSell—2.5M——3Y notice
6 May 2026Gregory CollierOther800k———3Y notice
Free account
7 notices on record — Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Free account: 2 full company unlocks every month, no card.
Create free accountSee plans

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Free account: 2 full company unlocks every month, no card.
Create free account

Latest announcements

30 Aug 2026$PAvecho enters final stage of Phase III insomnia trial
27 Aug 2026Notification regarding unquoted securities - AVE
25 Aug 2026$PAppendix 4D and Half-year Financial Report
23 Aug 2026Avecho strengthens BD capability with senior appointment
12 Aug 2026Small Holding Share Sale Facility Completion
2 Aug 2026Japanese patent granted for CBD capsule
28 July 2026$PJune 2026 Quarterly Activities Report & Appendix 4C
30 June 2026Application for quotation of securities - AVE
23 June 2026Positive Phase III Interim Analysis Results Investor Webinar
23 June 2026$PPositive interim results from Phase III insomnia program
22 June 2026Phase III Interim Analysis Outcome Webinar
21 June 2026$PTrading Halt
2 June 2026Notification regarding unquoted securities - AVE
31 May 2026Notification of cessation of securities - AVE
31 May 2026Final Director's Interest Notice
26 May 2026Small Holding Share Sale Facility
26 May 20262026 Annual General Meeting Results
26 May 2026Chair's Address and CEO Presentation
25 May 2026Resignation of Non-Executive Director
25 May 2026Investor Webinar Presentation

Headlines link to the source PDFs on the ASX announcements platform. Data as of 12 Sept 2026.